Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

IL-33, sST2 e PCR na Perturbação de Pânico

14 de novembro de 2026 atualizado por: Mehmet Hamdi ÖRÜM, Elazığ Mental Health and Diseases Hospital

Investigação da IL-33, sST2 e Proteína C-Reativa no Transtorno de Pânico: Um Estudo Transversal de Caso-Controle

Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.

Visão geral do estudo

Status

Concluído

Condições

Descrição detalhada

This is an observational, cross-sectional, case-control study conducted at the psychiatry outpatient clinic of Elazığ Mental Health and Diseases Hospital. It was planned to include 41 participants in the panic disorder (PD) and 30 healthy controls (HCs) groups. All participants will complete a sociodemographic data form and the DSM-5 Panic Disorder Severity Scale (Adult Form). Venous blood samples will be collected as 5 mL. Serum interleukin-33 (IL-33), soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels will be measured using commercially available ELISA kits. Statistical analyses will include independent samples t-test or Mann-Whitney U test, chi-square test, correlation, regression, and ROC analysis. A p value < 0.05 will be considered statistically significant.

Tipo de estudo

Observacional

Inscrição (Real)

71

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Elâzığ
      • Elâzığ, Elâzığ, Turquia (Türkiye), 23200
        • Elazığ Mental Health and Diseases Hospital Psychiatry Clinic

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

The study population consisted of adult participants aged 18-65 years. The panic disorder (PD) group included consecutive subjects diagnosed with PD according to DSM-5-TR criteria who were admitted to the psychiatry clinic of Elazığ Mental Health and Diseases Hospital (Turkey). The healthy control (HC) group consisted of individuals from the general population who applied to the hospital medical board and had no current or past psychiatric or significant medical disorders. All participants provided informed consent prior to enrollment.

Descrição

  1. For Panic Disorder (PD) Group:

    *Inclusion Criteria:

    • Being between 18-65 years of age

    • Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder
    • Not having previously used any medication for psychiatric purposes (drug-naive)
    • Not having any additional active psychiatric disorders besides PD at the current presentation
    • Absence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
    • Not having taken any medication or supplements in the last month
    • Completing sociodemographic and scale data fully
    • Volunteering to participate in the study

    For PD Group:

    *Exclusion Criteria:

    • Being outside the 18-65 age range

    • Not meeting the diagnostic criteria for PD according to DSM-5-TR or being in good health

    • Having a history of psychiatric medication use

    • Having an additional psychiatric disorder besides PD at the current application

    • Presence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, cancer
    • Taking any medication or supplement in the last month
    • Incomplete completion of sociodemographic and scale data
    • Not volunteering to participate in the study
  2. For Healthy Control Group:

    *Inclusion Criteria:

    • Being between 18-65 years of age

    • Not having any active psychiatric disorder

    • Not having previously used any medication for psychiatric purposes (drug-naive)

    • Not having hypertension, diabetes mellitus, kidney failure, liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer

    • Not having taken any medication or supplement in the last month
    • Completing sociodemographic and scale data fully
    • Volunteering to participate in the study

    For Healthy Control Group:

    *Exclusion Criteria:

    • Being outside the 18-65 age range
    • Having any active psychiatric disorder
    • Having a history of using psychiatric medication
    • Having hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
    • Taking any medication or supplement in the last month
    • Incomplete completion of sociodemographic and scale data
    • Not volunteering to participate in the study

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: CASE_CONTROL
  • Perspectivas de Tempo: CROSS_SECTIONAL

Coortes e Intervenções

Grupo / Coorte
Panic Disorder (PD)

Adult participants (18-65 years) diagnosed with panic disorder (PD) according to DSM-5-TR criteria. All of the subjects with PD was drug-naive. Subjects were evaluated at baseline. No intervention was assigned by the study protocol. Blood samples were collected for measurement of serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters. Clinical assessments in the PD group included the DSM-5 Panic Disorder Severity Scale (Adult Form). Sociodemographic and clinical data were recorded for all participants.

Healthy Control (HC)

Healthy control adult participants (18-65 years) without any current or past psychiatric disorder. No intervention was administered as part of the research protocol. Participants underwent a baseline clinical evaluation and provided a single blood sample for measurement of serum serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Interleukin-33 (IL-33)
Prazo: At hospital admission (baseline)

Interleukin-33 (IL-33) levels measured by ELISA (pg/ml).

At hospital admission (baseline)
Soluble Suppressor Tumorogenicity-2 (sST2)
Prazo: At hospital admission (baseline)

Soluble Suppressor Tumorogenicity-2 (sST2) levels measured by ELISA (pg/ml)

At hospital admission (baseline)
C-Reactive Protein (CRP)
Prazo: At hospital admission (baseline)

C-Reactive Protein (CRP) levels measured by ELISA (mg/dL)

At hospital admission (baseline)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Systemic Inflammation Response Index (SIRI)
Prazo: At hospital admission (baseline)

SIRI was calculated as (neutrophil count × monocyte count)/lymphocyte count. Laboratory staff were blinded to group status.

At hospital admission (baseline)
DSM-5 Panic Disorder Severity Scale-Adult Form (PDS)
Prazo: At hospital admission (baseline)

The DSM-5 Panic Disorder Severity Scale-Adult Form (PDS) is a 10-item self-assessment scale developed by the American Psychiatric Association (APA) that uses a five-point Likert scale (0=Never; 1=Sometimes; 2=Halfway through; 3=Most of the time; 4=Always). Participants consider how much their panic disorder has affected their personal lives in the past seven days when completing the scale. Scores obtained from the scale items indicate the severity of the panic disorder. The scale can be scored between 0 and 40, with higher scores indicating a more severe panic disorder. The mean total score is calculated by dividing the total raw score by the number of items on the scale.

At hospital admission (baseline)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

7 de julho de 2025

Conclusão Primária (Real)

5 de março de 2026

Conclusão do estudo (Real)

5 de março de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

25 de fevereiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de fevereiro de 2026

Primeira postagem (Real)

3 de março de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • EMHDH-2025-2026-PD-IL33-ST2-CR

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Deidentified individual participant data (IPD) underlying the results reported in this study (including demographic variables, serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2) and C-reactive protein (CRP) levels, complete blood count parameters, and DSM-5 Panic Disorder Severity Scale-Adult Form (PDS) will be made available to qualified researchers upon reasonable request for academic purposes. Data will be shared after removal of all direct identifiers and in accordance with applicable ethical approvals and data protection regulations. Access to the data will require a methodologically sound research proposal and a data use agreement. Requests should be directed to the corresponding author.

Prazo de Compartilhamento de IPD

Data will be available beginning 6 months after publication and will remain available for 5 years.

Critérios de acesso de compartilhamento IPD

Access will be granted to researchers who provide a methodologically sound proposal. Requests must be approved by the principal investigator and may require a data use agreement in accordance with institutional and ethical regulations.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever